Simultaneous TURP and TURBT Is Oncologically Safe

Background: Bladder cancer (BC) and benign prostatic hyperplasia (BPH) commonly coexist in elderly men, often necessitating transurethral resection of bladder tumor (TURBT) and transurethral resection of the prostate (TURP). Concerns have historically existed regarding the oncological safety of performing both procedures simultaneously, particularly due to the theoretical risk of tumor cell implantation in the prostatic fossa. Objective: To evaluate the oncological safety of simultaneous TURBT and TURP, with special emphasis on overall recurrence and prostatic urethral recurrence. Methods: This prospective observational study included 60 patients treated at the Department of Urology, Satkhira Medical College Hospital, from September 2023 to March 2025. Among them, 35 patients underwent simultaneous TURBT and TURP (Group 1), and 25 underwent TURBT alone (Group 2). Clinical, pathological, and follow-up data were analyzed using SPSS version 22. Student’s t-test and Chi-square or Fisher’s exact test were applied as appropriate. Statistical significance was set at p 0.05. Results: Recurrence was observed in 11.4% of patients in the simultaneous group compared to 28.0% in the TURBT-only group; however, the difference was not statistically significant (p = 0.102). Prostatic fossa recurrence showed no significant difference between groups. Postoperative complications were comparable. Conclusion: Simultaneous TURBT and TURP is oncologically safe and does not increase recurrence risk. It can be considered a feasible surgical approach in appropriately selected patients.